SciSparc Licenses SCI-160 Pain Drug Program to Polyrizon
Exploration of SciSparc’s Strategic Move Towards Pain Treatment
Klaus Vedfelt/DigitalVision via Getty Images Amid the ebbs and flows of the stock market, SciSparc (NASDAQ:SPRC) witnessed a staggering 40% surge in post-market trading on a particularly eventful Friday. This surge was the result of the Israeli pharmaceutical company’s strategic decision to exclusively license its SCI-160 pain treatment program to Polyrizon. In a mutually beneficial ...











